Mandeville Therapeutics is developing small molecule therapeutics to transform the treatment of chronic kidney disease. Chronic kidney disease affects over 35 million individuals in the US and there is a critical unmet need for new therapeutics. Mandeville’s lead program is designed to improve kidney function with a differentiated approach that targets the endothelin receptor, a clinically validated pathway and has the potential to reduce morbidity and mortality risk.